Showing 4171-4180 of 10903 results for "".
- Lebrikizumab Meets Primary Endpoints in Phase 3 ADorable-1 Trial for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-meets-primary-endpoints-in-phase-3-adorable-1-trial-for-pediatric-atopic-dermatitis/2487891/Lebrikizumab demonstrated significant improvements in disease severity and symptoms in infants, children, and adolescents with moderate-to-severe atopic dermatitis (AD), according to Week 16 results from the phase 3 ADorable-1 trial presented at the 2026 Society f
- Psychological Burden of Atopic Dermatitis Appears Greatest in Children and Adolescentshttps://practicaldermatology.com/news/psychological-burden-of-atopic-dermatitis-appears-greatest-in-children-and-adolescents/2487888/Children and adolescents with atopic dermatitis (AD) may experience a greater psychological burden than adults with the disease, according to a systematic review and meta-analysis published in Frontiers in Public Health.¹ However, investigators cautioned
- Farming-Associated Maternal Microbiome Linked With Lower Early Childhood Atopic Diseasehttps://practicaldermatology.com/news/study-farming-associated-maternal-microbiome-linked-with-lower-early-childhood-atopic-disease/2487882/A maternal gut microbiome shaped by a traditional farming lifestyle may help explain the protective effect of prenatal farm exposure against atopic disease in children, according to new research published in Allergy.
- Guideline-Based Management Limits Testing and Identifies Risk Factors for Chronic Urticaria in Childrenhttps://practicaldermatology.com/news/guideline-based-management-limits-testing-and-identifies-risk-factors-for-chronic-urticaria-in-children/2487889/Most children presenting with a first episode of acute urticaria (AU) recover with conservative, guideline-based management and require little diagnostic testing, according to a prospective cohort study published in Pediatric Allergy, Immunology, and Pulmonolog
- Text Messaging Intervention Improves Cardiovascular Risk Behaviors in PsO Trialhttps://practicaldermatology.com/news/text-messaging-intervention-improves-cardiovascular-risk-behaviors-in-pso-trial/2487819/A structured text messaging intervention was shown to improve patient activation and several cardiovascular risk behaviors among adults with psoriasis, according to new findings published in JAMA Dermatology.
- LEO Pharma Reports Positive Phase 2 Pediatric Data for Tralokinumab in Atopic Dermatitishttps://practicaldermatology.com/news/leo-pharma-reports-positive-phase-2-pediatric-data-for-tralokinumab-in-atopic-dermatitis/2487767/LEO Pharma has announced positive topline results from the Phase 2 TRAPEDS-1 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD).
- Teva Advances Anti-IL-15 Antibody Into Phase 2b for Vitiligohttps://practicaldermatology.com/news/teva-advances-anti-il-15-antibody-into-phase-2b-for-vitiligo/2487696/Teva Pharmaceutical Industries Ltd. has announced plans to advance its investigational anti-interleukin-15 (IL-15) monoclonal antibody (TEV-'408) into a Phase 2b clinical trial for non-segmental vitiligo (NSV) in the fourth quarter of 2026 following encouraging in
- Commentary Proposes Path to Cutting Plastic Waste in Dermatology Researchhttps://practicaldermatology.com/news/commentary-highlights-practical-route-to-cutting-plastic-waste-in-dermatology-research/2487685/The redesign of laboratory packaging to reduce plastic waste is a feasible near-term strategy for reducing plastic waste in skin-model research without disrupting validated experimental systems, according to a commentary in the Journal of Investigative Dermato
- FDA Expands ZORYVE Cream Approval to Children as Young as 2 Years With Plaque Psoriasishttps://practicaldermatology.com/news/fda-expands-zoryve-cream-approval-to-children-as-young-as-2-years-with-plaque-psoriasis/2487622/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) expanding the indication for ZORYVE (roflumilast) cream 0.3% to include the topical treatment of plaque psoriasis, including intertriginous areas, in children as young as 2 yea
- Emblation Partners With DermLite to Expand Access to Dermoscopy for Podiatristshttps://practicaldermatology.com/news/emblation-partners-with-dermlite-to-expand-access-to-dermoscopy-for-podiatrists/2487590/Emblation has announced a new collaboration with DermLite that will make the DermLite DL1 dermatoscope available through the Swift store, expanding access to dermoscopy tools for podiatrists using the company's Swift microwave therapy platform.